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Abstract
Background: Neutralizing antibodies (NAbs) against Interferon beta (IFNβ) are reported to be
associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to
quantify the contribution of NAbs to the sub-optimal response of IFNβ treatment.
Methods: We studied the prevalence of NAbs in MS patients grouped according to their clinical
response to IFNβ during the treatment period. Patients were classified as: group A, developing ≥
1 relapse after the first 6 months of therapy; group B, exhibiting confirmed disability progression
after the first 6 months of therapy, with or without superimposed relapses; group C, presenting a
stable disease course during therapy. A cytopathic effect assay tested the presence of NAbs in a
cohort of ambulatory MS patients treated with one of the available IFNβ formulations for at least
one year. NAbs positivity was defined as NAbs titre ≥ 20 TRU.
Results: Seventeen patients (12.1%) were NAbs positive. NAbs positivity correlated with poorer
clinical response (p < 0.04). As expected, the prevalence of NAbs was significantly lower in Group
C (2.1%) than in Group A (17.0%) and Group B (17.0%). However, in the groups of patients with
a poor clinical response (A, B), NAbs positivity was found only in a small proportion of patients.
Conclusion: The majority of patients with poor clinical response are NAbs negative suggesting
that NAbs explains only partially the sub-optimal response to IFNβ.
Background
The clinical efficacy of Interferon beta (IFNβ) therapy in
Multiple Sclerosis (MS) has been demonstrated consist-
ently in large, randomized, placebo-controlled trials [1].
However, a proportion of treated patients ranging from
7% to 49% show a poor clinical response [2].
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Mechanisms underlying IFNβ activity in MS are only par-
tially known. There is evidence suggesting that the interac-
tion between IFNβ and its receptor is responsible for
beneficial effects of IFNβ [3,4]. Exposure to IFNβ, how-
ever, can result in the development of antibodies against
the IFNβ [5,6]. Neutralizing antibodies (NAbs) interact
with the biologically active sites of the IFNβ molecule,
preventing the interaction of IFNβ with its receptor and
downstream effects. Binding antibodies (BAbs) may bind
to several different antigenic epitopes of the IFNβ mole-
cule, some of which are not involved in the activation of
IFNβ receptors [7]. Moderate or high levels of BAbs devel-
oped during the first year of IFNβ treatment may predict
of the subsequent development of NAbs [8].
The development of NAbs can reduce or abrogate IFNβ
bioavailability, as revealed by decreased levels of biologi-
cal markers of IFNβ bioactivity, such as neopterin, β2-
microglobulin, and myxovirus resistance protein A, and
the reduction in IFNβ bioavailability may depend on
NAbs titres [9-13]. In treated MS patients IFNβ bioactivity
decreases as NAbs develop, returning to the normal levels
when NAbs levels fall [14]. In NAbs-negative patients an
in vivo biological response to IFNβ is present, which is not
detectable in patients with high NAbs titres [15].
Although the relationship between induction of biologi-
cal markers and IFNβ clinical activity is not known, this
evidence suggests that NAbs detected by validated in vitro
assays may have consequences in vivo.
NAbs against IFNβ have been largely studied as one of the
factors responsible for poor clinical response to therapy in
MS. Although many studies have shown that NAbs reduce
IFNβ efficacy, as measured by MRI and clinical disease
activity [5,10,16-25], the clinical relevance of NAbs, espe-
cially at low titres, in MS patients treated with IFNβ
remains debatable [26,27].
It remains, however, to be established whether NAbs play
a major role in determining a poor clinical response to
IFNβ. Here, we aim to quantify the percentage of NAbs
positivity among sub-optimal responder patients to deter-
mine to what extent NAbs contribute to IFNβ response in
MS. This could inform clinicians on the contribution of
NAbs detection to IFNβ response and support clinical
decision making.
Methods
Patients
We included patients with a diagnosis of relapsing-remit-
ting MS (RRMS) or secondary-progressive MS (SPMS) [28]
receiving IFNβ treatment as a first line therapy and under-
going routine assessment at the MS University Outpatient
Services of Rome, "Sapienza" University, and Naples,
"Federico II" between January 2004 and December 2005.
Patients aged from 18 to 55 years were eligible if they had
a score of 6.0 or lower on the Expanded Disability Status
Scale (EDSS) [29]. Patients with RRMS should have expe-
rience at least two relapses supported by history and con-
firmed by physical examination, during the 2 years prior
to the commencement of therapy. Patients with SPMS
were eligible if they had experienced a sustained disability
progression for at least 6 months after an initial RRMS
course of disease. Only patients taking IFNβ therapy for at
least 12 months prior to study entry were included. RRMS
patients were undergoing treatment with standard doses
of one of the IFNβ formulations available; treatment for
SPMS was restricted to IFNβ-1b, the only drug licensed in
Italy for treatment of SPMS. The Ethics Committees of the
two University Hospitals approved the study.
Demographic and clinical assessments
Demographic and clinical data were regularly recorded at
each 6-month visit on the on-site database.
A relapse was defined as the appearance or re-appearance
of one or more symptoms attributable to MS, accompa-
nied by objective deterioration lasting at least 24 hours on
neurological examination, in the absence of fever, and
preceded by neurological stability for at least 30 days [30].
The relapse were assessed by a trained neurologist and in
the event of a disabling relapse, patients received a stand-
ard course of steroids (methylprednisolone, 1 g/day intra-
venously) for 5 days.
Definitions of response to IFNβ therapy
We defined three groups of patients according to the clin-
ical response to IFNβ, based on disability progression and
the number of relapses over the study period:
Group A
patients experiencing relapses without confirmed disease
progression during the treatment period before NAbs test-
ing. Relapses occurred in the first 6 months of therapy
were not counted.
Group B
patients who experienced an increase of ≥ 1.0 point of the
EDSS, or ≥ 0.5 points if baseline EDSS score was ≥ 5, with
confirmed disease progression at 6 months, persisting for
at least 2 consecutive scheduled visits, with or without
superimposed relapses during the treatment period; the
EDSS at the time of the relapse was not considered in the
definition of disease progression. Patients without a con-
firmatory exam were excluded from the study.
Group C
patients with a clinically stable disease, i.e. without
relapses and/or disability progression during the study
period. Within each group, patients were stratified accord-BMC Neurology 2009, 9:54 http://www.biomedcentral.com/1471-2377/9/54
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ing to the type of IFNβ formulation with which they were
treated.
Twelve out of 141 patients (8.5%) were treated with IFNβ-
1a 30 mcg (Avonex®; Biogen Idec, Cambridge, MA),
administered intramuscularly once a week (hereafter
'Avonex'); 36 (25.5%) were treated with IFNβ-1b 8 MIU
(Betaferon®; Bayer-Schering Pharma, Berlin, Germany),
administered subcutaneously every other day (hereafter
'Betaferon'); 48 (34.0%) were treated with IFNβ-1a 22
mcg (Rebif 22®; Merck Serono International S.A., Geneva,
Switzerland, an affiliate of Merck KGaA, Darmstadt, Ger-
many), administered three times a week (hereafter 'Rebif
22'); and 45 (31.9%) patients were treated with IFNβ-1a
44 mcg (Rebif 44®; Merck Serono International S.A.,
Geneva, Switzerland, an affiliate of Merck KGaA, Darm-
stadt, Germany), administered three times a week (hereaf-
ter 'Rebif 44').
NAbs assessment
A blood sample was taken once during the study, at least
12 months after starting IFNβ treatment, to test for the
presence of NAbs (Figure 1). Patients did not receive cor-
ticosteroids in the month preceding blood sampling and
had not been treated with immunosuppressive drugs
associated with IFNβ. At the time of blood sampling,
EDSS was assessed. Response to therapy, i.e. patients' clas-
sification into groups A, B or C, was defined on the basis
of the neurological assessment performed at the time of
blood sampling for the NAbs test.
Blood samples were allowed to clot at room temperature
for an hour prior to centrifugation. Sera were collected
and stored at -20°C in small aliquots until analysis. The
presence of NAbs to IFNβ was tested using a cytopathic
effect (CPE) assay against 10 IU of recombinant IFNβ-1a
or IFNβ-1b [31]. Sera were inactivated at 56°C for 30 min-
utes before titration. Two-fold serial dilutions (starting
from 1:10) of sample or control sera in 60-μL volumes
were incubated with 60 μL of 20 IU/mL of each type of
IFNβ at 37°C for an hour. Next, 100 μL of individual sam-
ple mixtures were added to duplicate monolayers of
human lung carcinoma (A549) cells in 96-well microtitre
plates. After 18 to 24 hours of culture and extensive wash-
ing, cells were exposed to encephalomyocarditis virus, fol-
lowed by incubation at 37°C for 24 hours. Controls
included a titration of the IFN preparation used in the
assay.
Antiviral activity and its neutralization were assessed on
the basis of virus-induced CPE. To quantify the CPE, cells
were stained with crystal violet in 20% ethanol, followed
by elution of dye taken up by the cells with 33% acetic
acid. The extent of virus-induced CPE, its inhibition by
recombinant IFNβ, and the reversal of this by NAbs were
shown by the amount of dye eluted from each sample.
Titres were calculated using Kawade's method [32], and
Timeline of the study Figure 1
Timeline of the study. The blood sample to test for the presence of NAbs was taken once during the study, at least 12 
months after starting IFNβ treatment. Relapses or EDSS progression occurred in the first 6 months of therapy were not 
counted.BMC Neurology 2009, 9:54 http://www.biomedcentral.com/1471-2377/9/54
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expressed as ten-fold reduction units (TRU), namely, the
dilution of serum that reduces 10 laboratory units (LU)
per mL of IFN to 1 LU/mL [33]. Serum samples underwent
routine assay and were found to be free of endogenous or
residual IFN activity. None of the sera showed an intrinsic
antiviral activity and therefore no sera were excluded.
Patients were classified according to their NAbs status into
NAbs-negative and NAb-positive patients. NAbs-positiv-
ity was defined as a titre of ≥ 1:20 neutralizing units. Once
classified as NAbs-positive or NAbs-negative, patients
kept their classification for the duration of the study
according to the definition "anytime positive, always pos-
itive" [16].
Statistical analysis
The influence of NAbs on clinical efficacy, including clin-
ically documented relapses and confirmed disability pro-
gression, was tested. Differences between groups were
analyzed using nonparametric tests (Pearson chi-squared
test) for qualitative and categorical variables, and para-
metric tests (Student's t-test for independent samples or
univariate analysis of variance) for quantitative variables.
The Bonferroni post-hoc test was used for multiple compar-
isons and the paired t-test was used to compare the same
variables at different times. Analyses were performed
using SPSS version 8.0 software (SPSS Inc., Chicago,
USA). Significance was set at p < 0.05.
Results
Baseline demographic and clinical characteristics
Data were collected retrospectively from 141 patients (90
women and 51 men) with a mean (± standard deviation,
SD) age of 38.6 (± 9.7) years, disease duration since the
first clinical event suggestive of MS, of 10.98 (± 6) years
and a median EDSS score of 2 (range: 0-6.0). The mean (±
standard deviation, SD) of treatment duration before
Nabs testing was 4.3 (± 2.1) years (range 1-10).
Patients treated with Betaferon were older and had higher
baseline EDSS scores than patients treated with Rebif 22
or Rebif 44 (Table 1). Durations of disease and treatment
were also longer in the Betaferon- than in Rebif-treated
patients.
When the entire cohort of patients was grouped according
to the clinical response, within each group (n = 47), 4
patients were treated with Avonex, 12 with Betaferon, 16
with Rebif 22, and 15 with Rebif 44. The three response
groups were similar in terms of baseline demographic and
clinical characteristics (Table 2).
NAbs status and clinical response to IFNβ therapy
The presence of NAbs was tested in all patients after start-
ing IFNβ treatment (median 4 years, range 1-10 years).
Fifty-nine (42%) patients were tested between the first
and the third year after the beginning of IFNβ, while 82
(58%) were tested after the third year of treatment.
Whole cohort
NAbs were detected in 17 patients (12.1%). Eight out of
17 NABs-positive patients were tested after the third year
of therapy. Seventy-four out of 124 NAbs-negative
(59.7%) patients were tested after the third year of ther-
apy.
Baseline demographic and clinical characteristics did not
differ between NAbs-positive and NAbs-negative patients
(Table 3), with the exception of age, as NAbs-negative
patients were younger (p < 0.05).
Treatment group
When NAb-positivity was assessed on the basis of the
treatment group, one patient (8.3%) treated with Avonex,
5 (13.9%) treated with Betaferon, 6 (12.5%) treated with
Rebif 22, and 5 (11.1%) treated with Rebif 44 were found
to be NAbs-positive (Table 3). No significant differences
Table 1: Baseline characteristics of the patients grouped according to the IFNβ formulation
Characteristics Avonex
n = 12
Rebif 22
n = 48
Rebif 44
n = 45
Betaferon
n = 36
p
Age (years) 39.9 ± 10.8
(27-64)
38.7 ± 9.1
(23-58)
35 ± 8.4
(21-58)
42.6 ± 10.1
(25-67)
0.04
Disease duration (years) 12.3 ± 6.6
(5-24)
9.9 ± 5.3
(2-24)
9.7 ± 5.4
(3-28)
13.6 ± 6.8
(3-34)
0.01
Therapy duration (years) 4.7 ± 1.7
(2-8)
4.2 ± 1.6
(1-9)
3.2 ± 1.8
(1-10)
5.7 ± 2.5
(1-10)
0.001
EDSS score 1.8 ± 1.0
(1-4.5)
1.9 ± 1.0
(0-5)
2.0 ± 1.2
(0-5.5)
2.65 ± 1.5
(0-6)
0.02
All values are mean ± SD (range)BMC Neurology 2009, 9:54 http://www.biomedcentral.com/1471-2377/9/54
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were observed between NAbs-positive and NAbs-negative
patients according to IFNβ preparation.
Response group
When the presence of NAbs was considered according to
the clinical response to therapy, a significant interaction
was found between clinical response and NAbs develop-
ment (p < 0.04). The prevalence of NAbs was higher in
groups showing poor clinical response (Group A: 17.0%;
Group B: 17.0%) than in patients with clinically stable
disease (Group C: 2.1%). However, within groups with a
suboptimal response (Group A and Group B) only 16 out
of 94 (17%) patients were NAbs-positive, whereas 78
were NAbs-negative (Figure 2). Forty-nine out of 78
(63%) NAbs-negative patients underwent the blood sam-
pling after the third year of therapy.
Discussion
This study shows that the prevalence of NAbs is higher in
patients who experience relapses or disability progression
during IFNβ therapy than in patients with stable disease.
However, NAbs seem to explain only partially the poor
clinical response to IFNβ treatment, as only a small pro-
portion of patients with poor response to IFNβ become
Nabs-positive while on disease modifying treatment.
The development of NAbs has been reported to reduce
treatment efficacy [5,16,34] and their clinical relevance is
correlated with titre and persistence of antibodies. High-
titre, persistent NAbs have been consistently shown to
impair the activity of IFNβ, whereas low-titre NAbs appear
to have a milder effect [26,35-37]. In the present study,
NAbs status accounted for a small percentage of non-
responders: only 17.0% (16/94) of patients with either
Table 2: Baseline characteristics of the patients grouped according to the clinical response to IFNβ
Characteristics Group A
(n = 47)
Group B
(n = 47)
Group C
(n = 47)
p
Age (years) 38.2 ± 10
(23-64)
40.4 ± 10.8
(21-67)
37.3 ± 7.9
(23-56)
0.29
Disease duration (years) 10.6 ± 5.3
(3-24)
12.5 ± 6.3
(4-34)
9.9 ± 6.3
(2-28)
0.11
Therapy duration (years) 4.4 ± 2.3
(1-10)
4.1 ± 1.9
(1-10)
4.3 ± 2.2
(1-10)
0.79
All values are means ± SD(range)
Group A: patients experiencing at least one relapse after the first 6 months of therapy without confirmed disease progression. Group B: patients 
experiencing a sustained disability progression (increase of ≥ 1.0 point on the EDSS, or ≥ 0.5 points if baseline EDSS score was ≥ 5.5) with or 
without superimposed relapses during the treatment period. Group C: patients with a stable disease, i.e., no relapse and/or disability progression.
Table 3: Baseline characteristics of the patients grouped according to the presence of Nabs
Characteristics NAbs status P
Negative
(n = 124)
Positive
(n = 17)
Gender
Female 80 [64.5] 10 [58.8] 0.65
Male 44 [35.5] 7 [41.2] 0.65
Age (years) 38 ± 9.4 (21-64) 43 ± 10.8 (31-67) 0.046
Disease duration (years) 11 ± 5.8 (2-29) 11 ± 7.4 (3-34) 0.92
Treatment duration (in years) 4 ± 2.2 (1-10) 4 ± 1.7 (1-7) 0.14
IFNβ type 0.96
Avonex (n = 12) 11 [8.9] 1 [5.9]
Betaferon (n = 36) 31 [25.0] 5 [29.4]
Rebif 22 (n = 48) 42 [33.8] 6 [35.3]
Rebif 44 (n = 45) 40 [32.3] 5 [29.4]
Data are percentage [%] or mean ± SD (range)BMC Neurology 2009, 9:54 http://www.biomedcentral.com/1471-2377/9/54
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relapses or disease progression over the treatment period
were NAbs-positive at the time of blood sample. Although
the impact of IFNβ is different in RRMS and SPMS [1] and
IFNβ mainly acts as anti-inflammatory drug, in our study
the prevalence of NAbs was similar in Group A and B. This
may suggests that the development of NAbs abrogating
IFNβ bioavailability have the same negative influence on
disease worsening both in terms of relapses and EDSS pro-
gression.
The low prevalence of NAbs in patients with poor
response to therapy brings into question the clinical
impact of these antibodies on treatment efficacy. Absence
of NAbs does not guarantee IFNβ efficacy, as a large pro-
portion of patients who experience relapses or disability
progression do not develop NAbs. Indeed, risk factors for
a poor response to therapy that are independent from
NAbs status have been described. Genetic polymorphisms
may constitute intrinsic determinants of individual differ-
ences in response to IFNβ [38,39].
The contribution of NAbs to clinical response to IFNβ
depends on the definition of responders. Previously, dif-
ferent definitions of non-responders to IFNβ therapy have
been proposed but none of them have been validated in
long-term follow-up studies [2,40]. A reduction in the
number of relapses was used to define responders to ther-
apy. However, this definition is weakened by the phe-
nomenon of 'regression to the mean' [2]. In this study,
responders were defined as patients who had never expe-
rienced a relapse during treatment. We used disability pro-
gression confirmed at 6 months to identify patients with
a poor response; this definition has been shown to have
good sensitivity and specificity [2].
NAbs development was not predictable on the basis of
baseline characteristics. We did not find significant rela-
tionships between NAbs status and baseline characteris-
tics. However, younger patients were marginally more
likely to remain NAbs-negative than older patients [18].
The overall prevalence of NAbs observed in this study
(12.1%) was lower than reported previously [5,15-17],
but was similar to that shown in patients treated with
IFNβ for 3 to 10 years [41]. Several factors may explain
these differences in prevalence.
NAbs appearance may have been influenced by the defini-
tion of NAbs positivity. Here we used an "any-time posi-
tive, always positive" definition, testing patients only once
to determine the presence of NAbs. As we used the single-
sample method and obtained samples at variable time
intervals from the beginning of therapy ranging from 1 to
10 years, fluctuations in NAbs titres (and NAbs status)
cannot be completely ruled out. Previous studies have
shown that NAbs can be transitory and that some NAbs-
positive patients, particularly those with low titers, may
sero-revert to a negative status over time despite ongoing
IFNβ treatment [7,16,31]. The low prevalence of NAbs
(12.1%) in this study, especially in patients treated with
INFβ-1b, may be related to the longer duration of treat-
ment. Indeed, 58 patients were tested for NAbs after the
third year of treatment, allowing for sufficient time for
NAbs to disappear. Therefore, many of the NAbs-negative
patients could have been positive during the first years of
treatment. It has been shown that, returning to a NAbs-
negative state, treated patients may regain a biologic
response to IFNβ [42], but whether this will result in a res-
toration of the therapeutic efficacy remains unclear. A
recent study suggests that after reverting from a NAbs-pos-
itive to a NAbs-negative status, the therapeutic effect of
IFN-β-1b on relapses is restored [43].
Conclusion
Although evidence suggests that the development of NAbs
can adversely affect IFNβ efficacy, we suggest that NAbs-
positivity explains the poor response to IFNβ treatment
only in a small proportion of patients with MS and their
appearance should be weighted against other factors ham-
pering the response to treatment.
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Prevalence of NAbs according to the clinical response Figure 2
Prevalence of NAbs according to the clinical 
response. Within the groups of patients showing poor clini-
cal response (Group A and B), only 16 out of 94 patients 
(17.0%) are NAb-positive and 78 (83%) are NAb-negative. 
This suggests that NAbs presence explains only partially the 
poor clinical response to IFNβ.
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